Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Koessler, Thibaud, Alsina, Maria, Arnold, Dirk, Ben-Aharon, Irit, Lutz, Manfred P., Obermannova, Radka, Peeters, Mark, Sclafani, Francesco, Smyth, Elizabeth, Valle, Juan W., Wagner, Anna Dorothea, Wyrwicz, Lucjan, Fontana, Elisa, Moehler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381132/
https://www.ncbi.nlm.nih.gov/pubmed/34426663
http://dx.doi.org/10.1038/s41416-021-01474-y
Descripción
Sumario:Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

Ejemplares similares